Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider (PharmacoEconomics, (2014), 32, (735-743), 10.1007/s40273-014-0156-8);Modelling the cost effectiveness of interventions for osteoporosis: Issues to consider

PharmacoEconomics

Volumn 32, Issue 8, 2014, Pages 735-743

  Stevenson, Matt D ^a   Selby, Peter L ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC ASPECT; FRAGILITY FRACTURE; HEALTH CARE COST; HUMAN; JAW OSTEONECROSIS; MEDICAL HISTORY; MEDICAL TECHNOLOGY; MEDICATION COMPLIANCE; OSTEOPOROSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT PLANNING; WELLBEING; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; FRACTURES, BONE; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINE; STATISTICAL MODEL; UNITED KINGDOM;

BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES AS TOPIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84906935547     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0213-3     Document Type: Erratum

References (50)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 2003;94:646-50.
2. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series No. 843. Geneva: WHO; 1994.
3. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-41. (Pubitemid 24985932)
4. Torgerson DJ, Dolan P. The cost of treating osteoporotic fractures in the United Kingdom female population - the author replies. Osteoporos Int. 2000;11:551-2.
5. Burge RT, Worley D, Johansen A, Bhattacharyya S, Bose U. The cost of osteoporotic fractures in the UK: projections for 2000-2020. J Med Econ. 2001;4:51-2.
6. Weyler E, Gandjour A. Socioeconomic burden of hip fractures in Germany. Gesundheitswesen. 2007;69(11):601-6.
7. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011;22(6):1835-44.
8. Stevenson M, Lloyd Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess. 2009;13(45):1-134.
9. Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg. 1998;80:243-8.
10. Müller D, Pulm J, Gandjour A. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review. Value Health. 2012;15:284-98.
11. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:iii-iv, ix-xi, 1-158.
12. Panichkul S, Panichkul P, Sritara C, et al. Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women. Gynecol Obstet Invest. 2006;62:89-96. (Pubitemid 44200487)
13. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11:1-134.
14. TA160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://guidance.nice.org.uk/TA160/. Accessed Oct 2013.
15. TA161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. http://guidance.nice.org.uk/TA161/. Accessed Oct 2013.
16. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298(6):629-37. (Pubitemid 47236414)
17. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-39. (Pubitemid 30174026)
18. Kanis JA, Brazier J, Stevenson M, Lloyd-Jones M, Calvert NW. Treatment of established osteoporosis. Health Technol Assess. 2002;6(29):1-146.
19. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modelling in conjunction with individual patient simulation modelling. A case study describing the calculation of cost-effectiveness ratios for the treatment of osteoporosis. Med Decis Making. 2004;24:89-100. (Pubitemid 38116861)
20. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14:339-47. (Pubitemid 40514748)
21. National Institute for Health and Care Excellence. Process and methods guides. Guide to the methods of technology appraisal 2013. http://www.nice.org. uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed Oct 2013.
22. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175-9. (Pubitemid 38391531)
23. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42(1):4-15.
24. Stevenson M. The population of health economic models is critical. Bone. 2008;43:214.
25. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
26. Schousboe JT, Gourlay M, Fink HA, Taylor BC, Orwoll ES, Barrett-Connor E, et al. Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight. Osteoporos Int. 2013;24(1):163-77.
27. FRAX®. WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/ . Accessed Oct 2013.
28. Stevenson M. Assessing the feasibility of transforming the recommendation in TA160, TA161 and TA204 into absolute 10-year risk of fracture. http://www.nice.org.uk/nicemedia/live/11746/65031/65031.pdf. Accessed Oct 2013.
29. Black DM, Schwartz AV, Ensrud KE, et al. Effects of stopping or continuing alendronate after 5 years of treatment. JAMA. 2006;296(24):2927-38.
30. Ades AE, Lu G, Claxton K. Expected values of sample information calculation in medical decision making. Med Decis Making. 2004;24:207-27. (Pubitemid 38391940)
31. Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making. 2009;29(6):678-89.
32. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23. doi:10.1002/jbmr.
33. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012;15(5):604-12.
34. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-8. (Pubitemid 44498580)
35. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-9. (Pubitemid 26147662)
36. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570-8. (Pubitemid 34925651)
37. Ades AE, Cliffe S. Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making. 2002;22:359-71. (Pubitemid 34791323)
38. Cummings SR, Black DM, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-82. (Pubitemid 29014065)
39. McClung MR, Miller GP, Zippel H, Bensen WG, Roux C, Adami S. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333-40. (Pubitemid 32107641)
40. McClung MR, Boonen S, Törring O, Roux C, Rizzoli R, Bone HG, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. JBMR. 2012;27(1):211-8.
41. Borgström F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006;17:637-50.
42. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis J. Lifetime risk of hip fractures is underestimated. Osteoporos Int. 1998;8:599-603. (Pubitemid 28566977)
43. Meyer HE, Tverdal A, Falch JA, Pederden JI. Factors associated with mortality after hip fracture. Osteoporos Int. 2000;11:228-32. (Pubitemid 30216174)
44. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res. 1995;319:260-5.
45. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82. (Pubitemid 29126875)
46. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556-61.
47. Jalava T, Sama S, Pylkkanen L, Mawer B, Kanis JA, Selby P, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003;18:1254-60. (Pubitemid 37294918)
48. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15:108-12. (Pubitemid 38252423)
49. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18:95-109. (Pubitemid 28041646)
50. Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P. The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos. 2011;2011:259818. doi:10.4061/2011/259818.